Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXSCOT platform study in NAFLD with NASH-like biomarker phenotype
2019-000440-10Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LYS006 and tropifexor in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by Novartis. Primary endpoints: Safety endpoints and Adverse events. Started Jan 2020; status: terminated.
02
Drugs
LYS006tropifexor
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2019-000440-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000440-10.